Stocks · News reference

BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

Aug 5, 2026, 8:06 PMBenzinga Newsdesk

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 5, 2026, 8:06 PM
Checked: Aug 5, 2026, 8:06 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 20, 2026, 4:32 PMVandana Singh
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.
Read original at benzinga
ACIU
BenzingaAug 20, 2026, 2:30 PMBenzinga Newsdesk
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
Read original at benzinga
ACIU
BenzingaAug 20, 2026, 11:03 AMBenzinga Newsdesk
AC Immune Says NLRP3 Inhibitor ACI-19764 Safe And Well Tolerated In Phase 1 With Confirmed CSF Penetration; Initial Cardiovascular Risk Cohort Results Expected By Year End
Read original at benzinga
ACIU
BenzingaAug 11, 2026, 11:04 AMBenzinga Newsdesk
AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026
Read original at benzinga
ACIU